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An exploratory phase II biomarker-embedded trial (LPT109747; NCT00526669) designed to 
determine the association of lapatinib induced fluoropyrmiinde gene changes with efficacy of 
lapatinib plus capecitabine as first-line treatment for advanced gastric cancer (GC) or 
gastroesophageal junction (GeJ) adenocarcinoma independent of tumor HER2 status. Tumor 
biopsies obtained before and after 7-day lapatinib (1250mg) to analyze changes in gene 
expression, followed by a 14-day course of capecitabine (1000mg/m2 BID, 14/21 days) plus 
lapatinib 1250mg daily. Blood samples were acquired for pharmacokinetic analysis. Primary 
clinical objectives: response rate (RR), 5-month progression-free survival (PFS). Secondary 
objectives: overall survival (OS), PFS, time-to-response, duration-of-response, toxicity and 
identify associations between lapatinib pharmacokinetics and biomarker endpoints. Primary 
biomarker objectives: modulation of 5-FU-pathway genes by lapatinib, effects of germline SNPs 
on treatment outcome, and trough steady-state plasma lapatinib concentrations. 68 patients 
were enrolled; (75% GC, 25% GeJ). 12 patients (17.9%) had confirmed partial response, 31 
(46.3%) had stable disease, and 16 (23.9%) had progressive disease. Median PFS and OS 
were 3.3 and 6.3 months, respectively. Frequent AEs included diarrhea (45%), decreased 
appetite (39%), nausea (36%), and fatigue (36%). Lapatinib induced no changes in gene 
expression from baseline and no significant associations were found for SNPs analyzed. 
Elevated baseline HER3 mRNA expression was associated with a higher RR (33% vs 0%, 
p=0.008). Lapatinib plus capecitabine was well tolerated, demonstrating modest antitumor 
activity in patients with advanced GC. The association of elevated HER3 and RR warrants 




Gastric (GC) and gastroesophageal junction (GeJ) cancer is the fifth most common 
cancer worldwide, and the third leading cause of cancer-related deaths, with incident 
cases approaching one million annually (1,2). Recurrent and metastatic GC and GeJ 
cancer has a poor prognosis, with median survival of <1 year. Only 20% of cases are 
diagnosed at an early, potentially curable, stage (1,2). 
 
In patients with advanced GC, chemotherapy improves overall survival (OS) compared 
with best supportive care (3). Five classes of cytotoxic agents are utilized as first-line 
therapy and include fluoropyrimidines, platinums, taxanes, topoisomerase inhibitors and 
anthracyclines.  The REAL-2 study results indicate non-inferiority of  capecitabine plus 
platinum agent compared to 5-FU and cisplatin. For patients demonstrating human 
epidermal growth factor receptor 2 (HER2) overexpression or amplification, trastuzumab 
combined with systemic therapy has become the standard treatment (4). Combination 
regimens have been shown to increase efficacy with response rates (RR) ranging from 
30% to 50%, progression-free survival (PFS) of 3−7 months and OS of up to 11 months, 
but not without significantly increasing treatment-related toxicity (4–8). Given the high 
percentage of patients who fail to respond to current therapies there is a critical need for 
novel, effective and personalized therapeutic strategies for the treatment for GC. 
 
Capecitabine, an oral fluorouracil (5-FU) pro-drug, has demonstrated activity as a single 
agent in GC with a RR of 19−34% (4,9). Once activated, 5-FU inhibits the de novo 
synthesis of thymidylate by inhibiting thymidylate synthase (TS), depleting thymidylate 
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pools, essential for DNA replication and repair and inducing a thymineless state and 
growth arrest (10,11). 5-FU is subsequently inactivated in the liver by the enzyme 
dihydropyrimidine dehydrogenase (DPD) (10,11). Despite no clear consensus to date, 
numerous studies have demonstrated that elevated TS levels or overexpression is 
associated with resistance to 5-FU-based therapy (11–16) and studies have suggested 
that lapatinib may down-regulate TS expression, sensitizing cancer cells to  
fluoropyrimidines (17,18). 
 
In addition to cytotoxic agents, there has been an increase in the evaluation of targeted 
therapies for GC. One potential therapeutic target is the HER family (19,20). HER2 
overexpression or amplification has been reported in 6−33% of GC and GeJ, a similar 
rate to that observed in breast cancer (21–25). The largest analysis to date of the 
incidence of HER2 amplification in GC was from the Phase III ToGa trial, which 
evaluated the combination of trastuzumab with chemotherapy in patients with metastatic 
GC. The authors reported the overall rate of HER2 amplification to be 22%, with a 
higher percentage (34%) in patients with GeJ tumors (26). HER2 amplification and 
overexpression has been correlated with a poor prognosis, although this remains 
controversial in GC (24,27,28). In addition to HER2, epidermal growth factor receptor 
(EGFR) has been shown to be up-regulated in 8−18% of GC and GeJ tumors (29). 
 
Lapatinib, a small molecule, dual tyrosine kinase inhibitor targeting EGFR and HER2, 
was predicted to demonstrate significant clinical activity against GC, where HER2 is 
amplified and/or there is an overexpression of EGFR or HER2 (29,30). To date, 
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lapatinib appears to have minimal activity as a single agent in first-line therapy of 
advanced/metastatic GeJ and GC based upon preliminary data from Phase II and III 
clinical studies (31–33). Although the study investigating lapatinib as first-line therapy in 
patients with advanced or metastatic GC met first-stage criteria and went on to 
complete enrollment (31), the study investigating lapatinib in relapsed adenocarcinoma 
of the esophagus stopped early because of rapid progression of disease. However, in a 
Phase I lapatinib plus capecitabine trial, one of two subjects enrolled with recurrent GC 
experienced a prolonged partial response (PR),	 suggesting the potential benefit from 
combination with other cytotoxic agents and the necessity of identifying biomarkers for 
patient selection (34,35). 
 
Based on the evidence suggesting that expression of EGFR and HER2 in GC and GeJ 
tumors is associated with poor prognosis, an exploratory international, multicenter 
Phase II study investigating the association of lapatinib-induced fluoropyrimidine 
pathway gene expression changes with clinical outcome to lapatinib plus capecitabine 
in first-line advanced GC and GeJ cancers was conducted to evaluate both biomarker 
and clinical endpoints and identify patients most likely to respond or be resistant to this 
regimen. It is important to note that this study was conducted in an era prior to 
recognition of HER2 amplification or overexpression as a patient selection tool for 




PATIENTS AND METHODS 
Eligible patients had histologically-confirmed, newly-diagnosed, advanced metastatic or 
unresectable GC, including adenocarcinoma of the GeJ. Untreated was defined as no 
prior chemotherapy, no prior radiotherapy, and no targeted therapy. Partial gastrectomy 
was allowed. Patients were ≥18 years old, with an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0−2, and measurable disease according to 
Response Evaluation Criteria in Solid Tumors (RECIST), had no history of other 
malignancy, and were able to swallow and/or receive enteral medications via 
gastrostomy feeding tube (including the ability to absorb medication). Patients were 
required to have adequate, hepatic and renal function. Exclusion criteria included 
malabsorption syndrome or uncontrolled inflammatory gastrointestinal disease, a known 
history of uncontrolled or symptomatic angina, arrhythmias, congestive heart failure, 
dementia, or total gastrectomy. The study was approved by the Institutional Review 
Board at the University of Southern California (USC) and all patients provided sign 
informed consents in accordance with institutional and federal guidelines. 
 
Study design 
This Phase II study (GSK study number LPT109747; ClinTrials.gov NCT00526669) was 
an open-label, multi-center, global, single-arm design and was conducted in molecularly 
unselected untreated patients with advanced or metastatic GC, prior to HER2 patient 
selection as a requirement for HER2 targeted agents and was completed in 2011. The 
primary biomarker objective was to identify any change of intra-tumoral messenger RNA 
(mRNA) and protein levels of genes known to modulate 5-FU sensitivity including TS, 
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DPD, thymidine phosphorylase, and their relationship to the HER pathway(s) on Day 0 
through serum levels of lapatinib. The primary clinical objective of this study was to 
assess RR and PFS at 5 months’ post-treatment with combination of lapatinib plus 
capecitabine in unselected patients with advanced/metastatic GC. The secondary 
clinical objectives included: (i) assessment of OS, (ii) assessment of time to 
progression, (iii) time to response, (iv) duration of response, and (v) quantitative and 
qualitative toxic effects of the regimen.  
 
After initial tumor biopsy (or archived formalin-fixed, paraffin-embedded tissue acquired 
since diagnosis), lapatinib alone was given as a 7-day run-in at 1250 mg daily followed 
by a second biopsy. These biopsies were performed to determine lapatinib effects on 
the intratumoral gene expression profiles using quantitative real-time polymerase chain 
reaction (qRT-PCR). Failure to complete the second biopsy resulted in patient 
ineligibility for the primary study biomarker endpoint. The day of the second biopsy was 
designated as Day 0 of Cycle 1. On the following day, a 14-day course of capecitabine 
at a dose of 1000 mg/m2 twice daily was initiated in combination with the continuous 
daily dose of lapatinib 1250 mg, every 21 days. This regimen continued in the absence 




A complete medical and surgical history, physical examination, complete blood count 
(CBC), and chemistry profile were obtained prior to treatment initiation. Baseline 
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computed tomographic (CT) scans were obtained prior to commencing treatment. CBC 
and comprehensive chemistry profile were repeated on a weekly basis for the first 2 
weeks from the first day of treatment, and every 3 weeks for the subsequent 24 weeks. 
Echocardiograms were performed at baseline and every 12 weeks thereafter. Medical 
history, physical examination, and toxicity assessment per National Cancer Institute 
Common Toxicity Criteria 3.0 were conducted weekly during the first cycle and every 
cycle thereafter. CT scans were repeated every 6 weeks for first 24 weeks, then every 




Genotyping was conducted on DNA isolated from peripheral blood samples (56 eligible 
patients). Single nucleotide polymorphisms (SNPs) analyzed included those in cyclin D1 
(CCND1), cyclooxygenase 2 (COX2), EGF, EGFR, HER2, vascular endothelial growth 
factor (VEGF), interleukin 8 (IL-8), methylenetetrahydrofolate receptor (MTHFR), and 
TS. Genomic DNA was extracted using the QiAmp kit (Qiagen, Valencia, CA, USA). 
SNPs were tested using the PCR-restriction fragment length polymorphism technique 
as previously described.(34). Briefly, forward and reverse primers were used for 
amplification of the specific DNA amplicon, followed by digestion of PCR products with 
restriction endonucleases (New England Biolab, MA, USA). In the case of no 




Gene expression levels were quantified for TS, DPD, EGFR, HER2, and HER3 using 
TaqMan qRT-PCR on board an ABI PRISM 7900 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA). Following deparaffinization, laser capture micro-
dissection was used to isolate tumor tissue. RNA isolation and complementary DNA 
(cDNA) synthesis was performed using the method developed by Dr. Danenberg at 
USC (US Patent #6248535) as previously described(36).. Extracted mRNA served as a 
template for cDNA synthesis and subsequent RT-PCR quantification of mRNA 
expression. qRT-PCR conditions have been described previously.(36) 
 
Pharmacokinetic  assessments 
Blood samples for measurement of lapatinib plasma concentration were obtained 
immediately prior to the lapatinib doses on Days -7 and -1, and the last doses 
administered after 6, 12, 18, 30, 42, 54, 66, and 78 weeks of treatment. Blood samples 
were anti-coagulated with EDTA, centrifuged, and plasma separated for storage at or 
below -20˚C until analyzed. Samples were analyzed for lapatinib using a previously 
published (37) validated method based on protein precipitation, followed by high-
performance liquid chromatography tandem mass spectrometry analysis. The lower limit 
of quantification for lapatinib was 5 ng/mL using a 25 µL aliquot of human plasma with a 
higher limit of quantification (HLQ) of 5000 ng/mL. Concentrations above the HLQ were 
diluted and re-analyzed. The analytical runs met all predefined criteria. Precision and 




The intent-to-treat (ITT) population was the same as the safety population, consisting of 
all subjects who entered the study and received at least one dose of lapatinib. Change 
in biomarker expression level from baseline and following 7 days of lapatinib treatment 
was analyzed. Fisher’s exact test was used to analyze if there were significant 
associations between analyzed SNPs and response, and the log-rank test was used for 
PFS and OS. Determination of hazard ratios for SNP data was based on the method 
described by Berry et al. (38) The Wilcoxon signed rank test was used to determine if 
there were significant changes between pre- and post-treatment mRNA expressions 
levels. Fishers’ Exact test was used to determine if there were significant associations 
between pre-treatment mRNA expression levels and RR; log-rank tests were used in 
the analyses for PFS and OS. The cut-off for gene expression level comparisons were 
derived based on pre-defined, published method (39). P-values were not adjusted for 
multiple comparisons. These modest p-values were within the number expected to 
occur by random chance in a set of 56 total statistical tests.  
 
The RR and the PFS at 5 months were analyzed to address the primary clinical 
objective. Five-month PFS was defined as the percentage of surviving patients who 
were progression-free 5 months after the date of initial treatment, where a subject was 
considered progression-free without observation of disease progression or death due to 





From March 17, 2008 to April 13, 2011, 68 patients were enrolled in the trial and 67 
received at least one dose of study treatment (these 67 subjects were included in the 
ITT and safety populations). Of these 67, 56 had available samples for subgroup and 
biomarker analysis. Of the 68 patients, 52 (76%) completed the study. The most 
common reasons for premature withdrawal were loss to follow-up (n=3; 4%), and 
patients’ decision to withdraw (n=2; 3%). Baseline characteristics for the ITT population 
(n=67), and the subgroup with specimens available (n=56), are presented in 
Supplemental Table 1. Baseline characteristics and clinical outcome for the entire trial 
population and those patients with specimens available for molecular correlates were 
extremely well balanced (Supplemental Table 1 and Table 2). 
 
Treatment administration 
The median duration of lapatinib treatment was 13 weeks (range 1.4–87 weeks) and the 
median duration of capecitabine treatment 11.1 weeks (range 0.9–86 weeks). Reasons 
for treatment discontinuation include disease progression (67%), adverse events (AEs) 
(15%), patient decision (9%), other reasons (6%), consent withdrawal (1%), and death 
(1%).  
 
Response, PFS, and OS 
For the ITT population, the confirmed RR was 17.9% (95% confidence interval [CI]: 9.6, 
29.2). There were no complete responses. A best confirmed response of PR was 
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observed in 12 (17.9%) patients. Stable disease (SD) was observed in 31 
(46.3%) patients (Table 1). Sixteen (23.9%) patients had progressive disease (PD). A 
waterfall plot of tumor shrinkage among patients with evaluable unconfirmed response 
(n=61) is shown in Supplemental Figure 1. Ten patients experienced a reduction in 
tumor size of ≥40% and 29 patients had tumor shrinkage of >10%. The 5-month PFS 
was 28.7% (95% CI: 17.9, 40.3). The median PFS was 3.3 months (95% CI: 2.9, 4.3). 
The median OS was 6.3 months (95% CI: 5.0, 9.1).  
 
Toxicity 
AEs were reported by the vast majority of patients (64 patients, 96%) and approximately 
two-thirds of subjects had AEs considered related to study treatment (45 patients, 67%). 
Two deaths due to AEs were reported (pneumonia and a thrombo-embolic event) but 
neither were considered to be related to study treatment. Serious AEs (SAEs) were 
experienced by 22 (33%) patients, of which 4 (6%) were considered related to study 
treatment. AEs leading to discontinuation of study drug were reported by 10 (15%) 
patients. The most frequently reported AEs were diarrhea (30 patients, 45%), 
decreased appetite (26 patients, 39%), nausea (24 patients, 36%), and fatigue 
(24 patients, 36%). This is consistent with previous studies of lapatinib in combination 
with capecitabine. 
 
SNPs in the EGFR and fluoropyrimidine pathway and clinical outcome to lapatinib plus 
capecitabine 
Genetic SNPs were assessed from whole blood samples from 56 patients. A total of 11 
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polymorphisms were evaluated in 9 genes: CCND1, COX2, EGF, EGFR, HER2, IL-8, 
MTHFR, TYMS, and VEGF.  
 
Of the 11 SNPs analyzed, only the MTHFR A1298C rs1801131 demonstrated a 
statistically significant association with RR for patients treated with lapatinib plus 
capecitabine. RR, based on unconfirmed response, was higher in the MTHFR1298 A/A 
vs A/C, C/C polymorphism (39% vs 9%, p=0.023; Figure 1), but the association was not 
significant if only confirmed responses were considered (Table 2). No significant 
associations were observed between the remaining SNPs evaluated and RR, PFS, or 
OS. 
 
Gene expression and clinical outcome to lapatinib plus capecitabine 
Tumor cDNA from 38 samples were utilized to determine the effects of lapatinib on 
intratumoral mRNA levels of 5 genes in pre- and post-treatment biopsies: TS, DPD 
EGFR, HER2, and HER3. 
The primary biomarker analyses indicated that there was no significant change in 
gene expression levels from baseline following 7 days of treatment with lapatinib 
monotherapy (Table 3). Further analysis for changes in HER2 gene expression levels in 
HER2 amplified and non-amplified patients demonstrated that HER2 mRNA levels were 
higher in patients with amplified HER2 than those without HER2 amplification in tumor 
tissues prior treatment and post treatment (p=.025 and .002, respectively; 
Supplementary Table 1). No statistically significant changes in HER2 gene expression 
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were observed in the subset of HER2-amplified patients following lapatinib treatment 
(p=0.22, Supplementary Table 1). 
In the analyses gene expression results and clinical outcome variables, elevated 
HER3 gene expression was associated with a higher RR (Table 4). Specifically, RR 
were higher in patients with HER3 expression values greater than the established 4.51 
cut-off (33% vs 0%, p=0.008) (Table 4). Although not significant, high EGFR/HER1 
mRNA expression (>1.19, n=26) before treatment showed a trend toward an 
association with longer PFS compared with low EGFR/HER1 mRNA expression (≤1.19, 
n=11; p=0.097) (Table 4).  
 
Pharmacokinetic assessment 
Lapatinib plasma concentrations on day (-1) were measurable in 66 patients, ranging 
from 38 to 4459 ng/mL. There were no apparent relationships between lapatinib plasma 
concentration on day (-1) after a week of daily lapatinib dosing and mRNA expression 
levels of DPD, TS, EGFR, HER2, and HER3.  
 
Lapatinib plasma concentrations at week 6 were measurable in 46 patients, ranging 
from 7 to 5223 ng/mL. Although these samples were collected at steady state, 
concentrations within each subject fluctuated over the study period. Fluctuation, 
measured as the ratio of maximum to minimum values, was greater in subjects after 
partial gastrectomy, with a geometric mean ratio of 5.22 versus 2.29 in subjects with an 
intact stomach. Lapatinib plasma concentrations were lower in patients with prior partial 
gastrectomy (Table 5). Week 6 geometric mean (95% CI) concentration for patients with 
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intact stomach was 1027 (712–1482) ng/mL and for partial resected stomach was 175 
(68–452) ng/mL (p=0.001). There was no evidence that this translated into a difference 
in survival. Median (range) PFS was 115 (43–419) days in partial gastrectomy patients 
(n=6) and 90 (22–473) days in patients with intact stomachs (n=51). Tumor response 
was not lower in gastrectomized patients despite lower plasma exposure compared with 
patients with intact stomachs.   
 
Changes in tumor size were examined relative to Week 6 lapatinib concentration. Ratios 
of maximum decrease in SLD to baseline displayed no relationship in patients with PD 
or SD, but appeared to be a related in patients with PR (n=13), where higher 




Despite the availability of cytotoxic agents and increasingly effective chemotherapeutic 
regimens, the prognosis for patients with GC or GeJ adenocarcinoma remains poor. 
Current employed standard-of-care treatments for advanced GC include numerous 
regimens with the majority favoring fluoropyrimidine and platinum combinations. 
Although modest improvements in patient survival have been achieved in recent years, 
complex genetics, tumor heterogeneity and toxicity remains a consistent problem and 
limits the use of more aggressive multi-drug combinations, particularly in patients with 
poor performance status. In addition, many putative predictive and prognostic 
biomarkers have been analyzed, but with numerous conflicting reports, the goal of 
personalized chemotherapy treatment for GC remains a concept as opposed to a 
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reality. In this study, the combination of lapatinib and capecitabine demonstrated a 
manageable toxicity profile with the most frequent on-therapy AEs limited to diarrhea, 
decreased appetite, fatigue, and nausea. The antitumor activity observed was 
significant with a RR of 17.9% and a median OS of 6.3 months. However, in this setting, 
other recently evaluated combinations including those employing combinations of 
capecitabine with either oxaliplatin or cisplatin combinations have demonstrated 
improved clinical activity (5). 
 
HER2 amplification is observed in approximately 15% of patients with GC but the 
proporotion is higher in intestinal (33%) and lower in diffuse (6%) (40). Further, HER2 
has been reported as an independent prognostic and potentially predictive biomarker in 
GC, but the precise role it plays remains controversial, with some initial reports 
suggesting that HER2 amplification is associated with aggressive disease and poor 
clinical outcome (41). However, the randomized phase III trial in advanced GC (ToGA) 
in selected patients for HER2 overexpression or amplification, determined that HER2-
positivity, and the intestinal subtype were found to be factors associated with a more 
favorable survival in advanced GC (40). In addition to inhibiting HER2, lapatinib also 
targets EGFR, which is overexpressed in 8–18% of GC, and the contribution of this 
mechanistic component to the efficacy is less understood. The ToGA trial also 
established that adding the HER2-targeted monoclonal antibody trastuzumab to 
standard chemotherapy leads to a significant improvement in OS compared with 
chemotherapy alone. This set a new standard of treatment for patients with HER2-
positive GC, firmly establishing HER2 as an efficacious target in this disease (40). The 
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results of the ToGA trial provided sound rationale for the clinical evaluation of other anti-
HER2 agents for GC.  In the current analysis, neither EGFR nor HER2 mRNA 
expression, measured by qPCR, changed significantly from baseline following lapatinib 
treatment. Of note, the current study was initiated and conducted in an era prior to the 
establishment and routine implementation of testing for HER2 amplification and/or 
overexpression as a selection tool for identification of patients likely to benefit from 
HER2-targeted therapy.  
 
Preclinical analyses have reported that lapatinib can induce intratumoral gene 
expression changes in the 5-FU pathway, including the downregulation of TS, the 
primary target of fluoropyrimidine-based agents. Importantly, while TS overexpression is 
widely reported as an important mechanism of resistance to fluoropyrimidine-based 
therapies, validation and implementation as a predictive biomarker in the clinic is still 
needed (42). The lapatinib-induced transcriptional down-regulation of TS is reported to 
contribute to synergy between HER2-targeted agents and fluoropyrimidines in both 
breast and GC cells with HER2 amplification (17,18). One of the primary objectives of 
this study was to investigate the clinical relevance of these observations and assess the 
feasibility of this type of analysis via repeat biopsy in an unselected patient population 
Phase II biomarker-driven study. The gene expression analyses indicated no significant 
change in intratumoral gene expression from baseline levels following 7 days of 
treatment with lapatinib monotherapy. Interestingly, intratumoral gene expression of the 
molecular targets of lapatinib were not associated with any clinical outcome variables 
tested. Elevated HER3 gene expression was, however, associated with a significantly 
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improved RR to lapatinib plus capecitabine. Elevated HER3 was recently reported to be 
an independent poor prognostic marker in GC (43) and is proposed to amplify the 
oncogenic effects of increased expression of HER2 and EGFR (44). While increased 
HER3 expression has typically been reported as an acquired resistance mechanism to 
HER-targeted agents, several recent studies have reported improved outcome to 
lapatinib in patients with elevated HER3 at baseline. Specifically, elevated HER3 was 
associated with improved clinical outcome in patients with breast cancer who received 
lapatinib plus capecitabine (45). The HER2/HER3 heterodimeric complex is reported to 
induce the most potent dimeric signaling of all the possible combinations resulting in 
HER dimeric complexes (46). It is plausible that elevated expression of HER3 drives an 
increased rate of HER2 intracellular signaling and is thus more susceptible to 
neutralization, with lapatinib leading to an improved response.  
 
The pharmacokinetic data obtained in this study represents the longest duration of 
measurement during lapatinib therapy. The week 6 concentration was the most 
predictive of drug responses. This time point was also associated with the largest 
difference in plasma concentration between subjects with intact versus resected 
stomachs. Lower exposure and higher fluctuation is consistent with disrupted biliary 
recycling secondary to partial gastrectomy. Although limited, the data in this study 
suggests that partial gastrectomy should not affect response, suggesting little or no 
effect on tumor uptake, which may be more dependent on HER2 expression than on 
plasma lapatinib concentration. 
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This study demonstrates that biomarker-embedding, including somatic genotyping and 
tumoral gene expression analysis from serial biopsies is feasible in the context of global 
clinical trials. While the combination of lapatinib and capecitabine was well tolerated 
there was only modest antitumor activity, limiting this regimen as a treatment option for 
an unselected patient population in with advanced GC, The biomarker analysis 
suggests that patients with elevated intra-tumoral HER3 may have an increased 
likelihood of response in unselected HER2 amplified patients. 
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Table 1. Clinical outcome by patient cohort  
 




specimen (n=56)  
N (%) 
RECIST response, confirmed   
 Complete response 0 0 
 Partial response 12 (17.9) 10 (17.9) 
 Stable disease 31 (46.3) 25 (44.6) 
 Progressive disease 16 (23.9) 14 (25) 
 Inevaluable 8 (11.9) 7 (12.5) 
 RR (%) (95% CI*) 17.9 (9.6, 29.2) 17.9 (8.9, 30.4) 
   
RECIST response, unconfirmed   
 Complete response 0 0 
 Partial response 16 (23.9) 13 (23.2) 
 Stable disease 29 (43.3) 23 (41.1)  
 Progressive disease 16 (23.9) 14 (25) 
 Inevaluable 6 (8.9) 6 (10.7) 
 RR (%) (95% CI*) 23.9 (14.3, 35.9) 23.2 (13.0, 36.4) 
   
PFS   
 PFS rate at 5 months (%) (95% CI†) 28.7 (17.9%, 40.3%) 24.6 (14.0, 36.7%) 
 Median (95% CI†), months 3.3 (2.8, 4.3) 3.0 (2.6, 4.2) 
   
OS   
 Median (95% CI†), months 6.3 (5.0, 9.1) 5.8 (3.8, 8.6) 
*Based on exact 95% CIs. †Based on Log-Log Transformation.  
Abbreviations: CI, confidence interval; OS, overall survival; PFS, progression-free 





Table 2. Response, progression-free survival, and overall survival by polymorphisms and HER2 amplification status. 
 
  Response  Progression-free survival  Overall survival 














CCND1 A870G    0.71   0.32   0.73 
 A/A 16 2 (13%) 14 (88%)  3.0 (2.0, 4.2) 1 (Ref)  6.3 (3.3, 11.6) 1 (Ref)  
 A/G† 32 8 (20%) 32 (80%)  3.0 (2.6, 4.3) 0.74 (0.40, 1.37)  5.8 (3.5, 9.1) 1.12 (0.58, 2.19)  
 G/G† 8          
COX2 G765C    0.34   0.26   0.30 
 G/G 47 7 (15%) 40 (85%)  3.0 (2.5, 3.8) 1 (Ref)  5.4 (3.8, 8.1) 1 (Ref)  
 G/C† 2 3 (33%) 6 (67%)  5.7 (2.6, 5.8+) 0.63 (0.26, 1.48)  9.1 (3.5, 23.1) 0.62 (0.24, 1.57)  
 C/C† 7          
EGF A61G    0.73   0.92   0.85 
 G/G 19 3 (16%) 16 (84%)  3.1 (2.9, 4.3) 1 (Ref)  5.8 (3.7, 14.7) 1 (Ref)  
 G/A 27 6 (22%) 21 (78%)  2.9 (2.0, 4.3) 1.10 (0.59, 2.05)  5.6 (3.3, 8.6) 1.20 (0.62, 2.33)  
 A/A 10 1 (10%) 9 (90%)  2.6 (1.6, 8.6) 1.16 (0.51, 2.63)  8.1 (1.1, 15.9) 1.06 (0.45, 2.52)  
EGFR G497A    0.16   0.33   0.087 
 G/G 24 2 (8%) 22 (92%)  2.9 (2.5, 4.3) 1 (Ref)  4.2 (2.6, 8.6) 1 (Ref)  
 G/A† 24 8 (25%) 24 (75%)  3.3 (1.8, 4.3) 0.76 (0.43, 1.36)  7.3 (4.2, 14.8) 0.61 (0.33, 1.10)  
 A/A† 8          
HER2 G655A    0.48   0.82   0.45 
 A/A 35 5 (14%) 30 (86%)  2.9 (1.8, 4.2) 1 (Ref)  4.4 (3.5, 8.1) 1 (Ref)  
 A/G 21 5 (24%) 16 (76%)  3.8 (2.8, 4.4) 0.94 (0.53, 1.66)  8.6 (3.8, 14.7) 0.80 (0.43, 1.46)  
IL8 T251A    0.36   0.23   0.23 
 T/T 19 3 (16%) 16 (84%)  3.1 (1.7, 4.1) 1 (Ref)  5.4 (3.5, 7.3) 1 (Ref)  
 T/A 24 3 (13%) 21 (88%)  2.9 (2.5, 4.3) 0.86 (0.45, 1.65)  6.3 (3.1, 15.4) 0.61 (0.32, 1.19)  
 A/A 13 4 (31%) 9 (69%)  4.2 (3.0, 5.8) 0.54 (0.25, 1.20)  5.8 (2.0, 22.9) 0.58 (0.25, 1.36)  
MTHFR C677T    0.72   0.96   0.99 
 C/C 22 3 (14%) 19 (86%)  3.0 (1.7, 4.4) 1 (Ref)  8.1 (3.5, 11.6) 1 (Ref)  
 C/T† 26 7 (21%) 27 (79%)  3.0 (2.6, 4.2) 1.01 (0.57, 1.80)  5.0 (3.8, 7.3) 1.01 (0.55, 1.82)  
 T/T† 8          
MTHFR A1298C    0.16   0.071   0.23 
 A/A 31 8 (26%) 23 (74%)  3.0 (2.6, 5.3) 1 (Ref)  7.2 (4.2, 9.3) 1 (Ref)  
 A/C† 20 2 (8%) 23 (92%)  3.0 (1.7, 4.1) 1.63 (0.92, 2.91)  4.4 (3.0, 8.6) 1.42 (0.79, 2.56)  
 C/C† 5          
TS-5’UTR    1.00   0.87   0.26 
 2R/2R, 2R/3C, 3C/3C 20 3 (15%) 17 (85%)  3.1 (2.6, 4.4) 1 (Ref)  5.4 (3.1, 12.9) 1 (Ref)  
 2R/3G, 3G/3C 26 5 (19%) 21 (81%)  2.9 (1.8, 4.2) 1.07 (0.57, 2.01)  8.1 (3.8, 14.8) 0.67 (0.34, 1.33)  
 3G/G 10 2 (20%) 8 (80%)  2.8 (1.6, 4.3) 1.22 (0.56, 2.67)  4.2 (2.2, 8.6) 1.17 (0.51, 2.69)  
TS-3’UTR    0.75   0.97   0.68 
 +/+ 14 3 (21%) 11 (79%)  3.1 (1.7, 4.3) 1 (Ref)  5.4 (3.5, 11.4) 1 (Ref)  
 +/- 22 3 (14%) 19 (86%)  2.6 (1.8, 5.3) 0.96 (0.45, 2.05)  5.8 (2.9, 14.7) 0.73 (0.32, 1.64)  
	 26 
 -/- 20 4 (20%) 16 (80%)  3.0 (1.8, 4.3) 1.03 (0.49, 2.18)  6.1 (3.8, 8.6) 0.88 (0.40, 1.95)  
VEGF C936T    1.00   0.78   0.66 
 C/C 42 8 (19%) 34 (81%)  3.0 (2.8, 4.3) 1 (Ref)  5.8 (3.8, 9.1) 1 (Ref)  
 C/T† 12 2 (14%) 12 (86%)  2.6 (1.7, 4.3) 0.91 (0.48, 1.75)  5.6 (2.6, 8.1) 1.16 (0.59, 2.30)  
 T/T† 2          
HER2 status    0.66   0.95   0.80 
 Amplified 8 1 (13%) 7 (88%)  4.3 (1.6, 8.5) 1 (Ref)  6.3 (2.6, 16.7) 1 (Ref)  
 Not amplified 34 8 (24%) 26 (76%)  3.0 (2.8, 4.3) 1.02 (0.46, 2.28)  5.8 (3.8, 8.6) 1.10 (0.49, 2.47)  
*Based on Fisher’s exact test for response and log-rank test for PFS and OS. †Dominant model: combining patients carrying 
heterozygous and homozygous variant genotypes together for outcome analyses. ‡Based on the method described by Berry et al (38).. 
Abbreviations: CCND1, cyclin D1; CI, confidence interval; COX, cyclooxygenase; EGF, epidermal growth factor; EGFR, epidermal 
growth factor receptor; HER, human epidermal receptor; HR, hazard ratio; IL8, interleukin 8; MTHFR, methylenetetrahydrofolate 
receptor; OS, overall survival; PFS, progression-free survival; TS, thymidylate synthase; VEGF, vascular endothelial growth factor
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Table 3. Intratumoral gene expression by treatment 
 
  Prior treatment  Post treatment  Change (post-prior)  
Gene N Median (Min, Max) N Median (Min, Max)  N Median (Min, Max) P value* 
TS 38 3.16 (0.53, 9.57) 39 3.64 (0.67, 11.30) 34 0.38 (-2.33, 7.25) 0.10 
DPD 32 0.58 (0.14, 1.87) 33 0.68 (0.16, 2.71) 26 0.12 (-0.61, 1.04) 0.097 
EGFR/HER1 37 1.59 (0.51, 87.84) 37 1.73 (0.10, 89.64) 32 0.15 (-1.88, 41.89) 0.10 
HER2 33 0.04 (0.01, 0.49) 34 0.06 (0.01, 1.87) 28 0.01 (-0.29, 1.61) 0.26 
HER3 37 4.51 (1.25, 43.61) 40 6.18 (0.89, 12.86) 33 0.87 (-36.31, 8.18) 0.38 
*Based on the Wilcoxon signed rank test.  
Abbreviations: DPD, dihydropyrimidine dehydrogenase; EGFR, epidermal growth factor receptor; 
HER, human epidermal receptor; TS, thymidylate synthase
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Table 4. Response, PFS, and overall survival by pretreatment intratumoral gene expression 
 
  RECIST response  Progression-free survival  Overall survival 









TS†    0.61   0.29   0.20 
 ≤4.1 29 4 (14%) 25 (86%)  3.0 (1.7, 4.4) 1 (Ref)  11.6 (5.4, 15.4) 1 (Ref)  
 >4.1 9 2 (22%) 7 (78%)  4.3 (3.0, 8.6) 0.64 (0.27, 1.51)  7.8 (2.0, 12.9) 1.68 (0.72, 3.88)  
DPD‡    0.55   0.38‡   0.66 
 ≤0.86 27 6 (22%) 21 (78%)  3.0 (2.9, 5.3) 1 (Ref)  7.8 (5.4, 14.7) 1 (Ref)  
 >0.86 5 0 (0%) 5 (100%)  1.7 (1.5, 1.7) 2.76 (0.67, 11.41)  16.1+ (2.3, 16.1+) 0.72 (0.17, 3.11)  
EGFR/HER1†    0.65   0.097   0.74 
 ≤1.19 11 1 (9%) 10 (91%)  3.0 (1.7, 4.3) 1 (Ref)  14.8 (3.8, 16.9) 1 (Ref)  
 >1.19 26 5 (19%) 21 (81%)  4.2 (2.6, 5.8) 0.54 (0.24, 1.24)  7.8 (4.2, 14.7) 1.15 (0.50, 2.63)  
HER2†    1.00   0.30   0.92 
 ≤0.065 25 5 (20%) 20 (80%)  4.3 (2.9, 5.7) 1 (Ref)  11.4 (4.2, 14.7) 1 (Ref)  
 >0.065 8 1 (13%) 7 (88%)  2.6 (1.6, 4.3) 1.55 (0.63, 3.81)  5.4 (2.0, 16.9) 0.96 (0.39, 2.33)  
HER3‡    0.008   0.11‡   0.75 
 ≤4.51 19 0 (0%) 19 (100%)  3.0 (1.6, 4.3) 1 (Ref)  6.3 (3.5, 15.4) 1 (Ref)  
 >4.51 18 6 (33%) 12 (67%)  4.3 (3.0, 8.6) 0.40 (0.18, 0.91)  11.4 (7.2, 15.9) 0.89 (0.42, 1.88)  
*Based on Fisher’s exact test for response and log-rank test for PFS and OS.†The cut-off value of gene expression was based 
on our previous studies (31,38,47). ‡The cut-off value was based on the optimal cut point for PFS and p values were adjusted 
accordingly (48). §Based on the method described by Berry et al.(38). Abbreviations: CI, confidence interval; DPD, 
dihydropyrimidine dehydrogenase; EGFR, epidermal growth factor receptor; HER, human epidermal receptor; HR, hazard ratio; 
PFS, progression-free survival; TS, thymidylate synthase 
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Table 5. Lapatinib steady-state plasma trough concentrations (ng/mL) in gastric 
cancer subjects with and without prior partial gastrectomy.   
 
Parameter Intact stomach Resected stomach Ratio* 












*Ratio, comparing steady state plasma trough concentrations (ng/mL) between patients 
with GC with and without prior partial gastrectomy; geometric means, 90% CI. 






Figure 1. MTHFR A1298C rs1801131 polymorphism demonstrated a statistically 
significant association with RR for patients treated with lapatinib plus 
capecitabine.   
RR, based on unconfirmed response, was higher in the MTHFR1298 A/A vs A/C, C/C 
polymorphism (39% vs 9%, p=0.023). There were 28 patients that were homozygous for 
the A-allele, and 22 patients with the C-allele. However, the association was not 
significant if only confirmed responses were counted. Statistical analysis was run with 
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